Vir Biotechnology (VIR) announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating
- Vir Biotechnology Poised for Growth: Buy Rating Reiterated Amid Clinical and Financial Advancements
- Vir Biotechnology price target raised to $31 from $26 at Barclays
- Vir Biotechnology’s Transformative Year: Earnings Call Insights
- Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology